PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) saw a significant increase in short interest in the month of July. As of July 15th, there was short interest totaling 201,780 shares, an increase of 77.2% from the June 30th total of 113,864 shares. Approximately 504.5% of the company’s shares are sold short. Based on an average daily volume of 503,315 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Trading of PicoCELA

An institutional investor recently bought a new stake in PicoCELA stock. Jane Street Group LLC purchased a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned 18.92% of PicoCELA as of its most recent SEC filing.

Analyst Ratings Changes

PCLA has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of PicoCELA to a “hold” rating in a research note on Saturday, July 25th. Weiss Ratings upgraded PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

PicoCELA Stock Performance

PCLA stock traded up $0.12 during trading on Thursday, hitting $5.05. The company had a trading volume of 12,112 shares, compared to its average volume of 744,159. PicoCELA has a 1-year low of $1.35 and a 1-year high of $16.80. The firm has a 50-day moving average price of $5.74 and a 200-day moving average price of $4.33.

PicoCELA Company Profile

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.